Somatostatin triggers local cAMP and Ca2+ signaling in primary cilia to modulate pancreatic β-cell function
Somatostatin, released from δ-cells within pancreatic islets of Langerhans, is one of the most important negative regulators of islet hormone secretion. We find that islet δ-cells are positioned near, and release somatostatin onto, primary cilia of the other islet cell types, including insulin-secreting β-cells. Somatostatin activates ciliary somatostatin receptors, resulting in rapid lowering of the ciliary cAMP concentration which in turn promotes more sustained nuclear translocation of the cilia-dependent transcription factor GLI2 through a mechanism that operates in parallel with the canonical Hedgehog pathway and depends on ciliary Ca<sup>2+</sup> signaling. We also find that primary cilia length is reduced in islets from human donors with type-2 diabetes, which is associated with a reduction in interactions between δ-cells and cilia. Our findings show that islet cell primary cilia constitute an important target of somatostatin action, which endows somatostatin with the ability to regulate islet cell function beyond acute suppression of hormone release.
Authors
- Ceren Incedal Nilsson (ORCID: https://orcid.org/0000-0003-4155-7457)
- Özge Dumral (ORCID: https://orcid.org/0000-0002-9980-2702)
- Michele Solimena (ORCID: https://orcid.org/0000-0002-3653-8107)
- Olof Idevall‐Hagren (ORCID: https://orcid.org/0000-0002-0241-6304)
- Huixia Ren (ORCID: https://orcid.org/0000-0002-1761-6018)
- Gonzalo Sánchez (ORCID: https://orcid.org/0000-0003-4415-1866)
- Andreas Müller (ORCID: https://orcid.org/0000-0002-3560-5769)
- Bing Xie
Institutions
- Uppsala University (SE)
- Peking University (CN)
- Deutsches Diabetes-Zentrum e.V. (DE)
- German Center for Diabetes Research (DE)
- Center for Life Sciences (CN)
- University Hospital Carl Gustav Carus (DE)
- Paul Langerhans Institute Dresden (DE)
- Heinrich Heine University Düsseldorf (DE)
- Technische Universität Dresden (DE)
Publication Details
- Journal
- The EMBO Journal
- Published
- 2025-02-12
- DOI
- https://doi.org/10.1038/s44318-025-00383-7
- Citations
- 9
- Primary Topic
- Genetic and Kidney Cyst Diseases
- Type
- article
- Field-Weighted Citation Impact
- 16.36
Funders
- Eli Lilly and Company
- European Foundation for the Study of Diabetes
- Vetenskapsrådet
- Stiftelsen Familjen Ernfors Fond
- Uppsala Universitet
- Diabetesfonden
- Novo Nordisk Fonden
- Insamlingsstiftelsen Diabetes Wellness Network Sverige